Our collaborators

The Institute of Cancer Research collaborates with industrial, academic and hospital partners over a range of projects – from drug discovery programmes and biomarker studies, to the development of high intensity focussed ultrasound for the treatment of cancer.

Some of our recent collaborations have included:

Astex – a 3.5-year drug discovery collaboration aimed at identifying a preclinical candidate which inhibits the molecule MMSET.

AstraZeneca – a range of programmes and projects under a strategic alliance

BACIT – co-investment alongside Sareum and the CRT Pioneer Fund in the Chk1 drug development programme

CRT Pioneer Fund – a series of 4 collaboration and licence agreements on drug discovery programme

Domainex – providing chemistry support on a 5-year drug discovery collaboration funded by the Wellcome Trust

Elekta – a range of projects in the field of radiotherapy and imaging

Enzon pharmaceuticals – a biomarker collaboration 

Horizon – collaboration to identify synthetic lethal cancer targets using Horizon’s isogenic cell lines

Illumina, Inc. – collaborative development of a cancer susceptibility genetic screening panel – TruSight Cancer

Janssen – a 2.5-year drug discovery collaboration

Merck – a multi-programme drug discovery collaboration

Nuevolution – a drug discovery collaboration working on difficult to drug targets

Onyx – a clinical trial of a novel α-folate receptor-mediated thymidylate synthase inhibitor using a study drug that was developed at ICR

Phillips – A collaboration in the field of High Intensity Focused Ultrasound (HIFU) treatment aiming to evaluate and optimise novel applications of HIFU in the treatment of cancer

Ventana – a multi-program collaboration providing equipment and support for a number of projects

Other industrial collaborators include: Amgen, EMD Millipore, Genentech, GSK, Morphosys, Oncolytics, PreCOS, Roche, Sanofi Aventis, Symphogen and Teva.

 

 

Related news

Clinical trials pharmacy (Jan Chlebik for the ICR, 2014)
New trial design could improve early-stage cancer studies involving CAR-T therapies

10/07/26

Researchers have developed a new statistical approach that could help improve how early-stage cancer trials identify the safest and most effective doses of advanced therapies, such as CAR-T therapy.
See full story

Related blogs

David Bateson (credit: David Bateson)
“Without immunotherapy, I wouldn’t be here now. I feel so lucky” – David’s melanoma story

23/07/25 - David Bateson

David Bateson, 49, was first diagnosed with melanoma, a type of skin cancer, in December 2019. By August 2021, it had spread to his liver, lungs and spine. Thanks to immunotherapy, David has gone from having aggressive cancer to having no evidence of disease in his body. He explains why he now has hope for the future and a new-found appreciation of life…
See full story